Skip to main content

Table 1 Comparison of study variables between PD1 and PDL1 groups

From: Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

  Tumoral Background
PD1 p PDL1 p PD1 P PDL1 P
Negative
Frequency (%)
Positive
Frequency (%)
Negative
Frequency (%)
Positive
Frequency (%)
Negative
Frequency (%)
Positive
Frequency (%)
Negative
Frequency (%)
Positive
Frequency (%)
Gender Male 11 (50.0%) 11 (50.0%) 0.588a 37 (92.5%) 3 (7.5%) 0.396a 5 (22.7%) 17 (77.3%) 0.180a 39 (97.5%) 1 (2.5%) 0.363a
Female 2 (66.7%) 1 (33.3%) 9 (100.0%) 0 (0.0%) 2 (66.7%) 1 (33.3%) 9 (90.0%) 1 (10.0%)
Variant Pleomorphic 0 (0.0%) 1 (100.0%) 0.240a 3 (100.0%) 0 (0.0%) 0.999b 0 (0.0%) 1 (100.0%) 0.999a (100.0%) 0 (0.0%) 0.999b
Classic 16 (59.3%) 11 (40.7%) 57 (95.0%) 3 (5.0%) 9 (33.3%) 18 (66.7%) 60 (96.8%) 2 (3.2%)
Blastoid - - 3 (100.0%) 0 (0.0%) - - 3 (100.0%) 0 (0.0%)
Ki67  < 30% 1 (25.0%) 3 (75.0%) 0.999a 7 (100.0%) 0 (0.0%) 0.523a 1 (25.0%) 3 (75.0%) 0.999a 7 (87.5%) 1 (12.5%) 0.999a
 ≥ 30% 4 (36.4%) 7 (63.6%) 12 (80.0%) 3 (20.0%) 2 (18.2%) 9 (81.8%) 14 (93.3%) 1 (6.7%)
  1. a The Fisher exact test was used for the comparison
  2. b The Monte Carlo test was used for the comparison